甲状腺障害の世界市場規模：タイプ別、治療別、投与経路別、エンドユーザー別、地域別、範囲および予測

甲状腺障害の市場規模と予測

甲状腺障害の市場規模は2024年に24億6,000万米ドルと評価され、2026～2032年の予測期間中にCAGR 3.17％で成長し、2032年までに33億5,000万米ドルに達すると予測されます。

甲状腺障害の増加、新しい効果的な併用薬物療法の導入、効果的な併用薬物療法を必要とする症例の増加は、予測期間中の市場成長を促進すると予測される要因の一部です。世界の甲状腺障害市場レポートは、市場の全体的な評価を提供します。主要セグメント、動向、市場促進要因、抑制要因、競合情勢、市場で重要な役割を果たしている要因などを包括的に分析しています。

世界の甲状腺障害市場の定義

甲状腺障害は、甲状腺の適切な機能に影響を及ぼす病状です。甲状腺は、首の下の中央に位置する内分泌腺で、体内の様々な代謝活動を調節するのに役立つ甲状腺ホルモンの産生を担っています。甲状腺は、体の細胞が食物からエネルギーを利用する、代謝と呼ばれるプロセスをコントロールしています。特に代謝は、体温や心拍、カロリーの消費量に影響します。体に十分な甲状腺ホルモンがないと、人体のプロセスが遅くなります。

甲状腺が十分な甲状腺ホルモンを分泌していない場合（甲状腺機能低下症）、またはホルモンが過剰に分泌されている場合（甲状腺機能亢進症）、体の代謝と機能が障害されます。体内のヨード不足は、甲状腺障害を引き起こす大きな要因です。甲状腺の病気はすべて治療することができ、その結果、甲状腺機能を正常にすることができます。しかし、そのためには甲状腺の状態を正常に保つための薬物療法が必要になることが多いです。甲状腺障害患者のほとんどは、手術や放射性ヨード治療によって治癒することができます。

世界の甲状腺障害市場概要

市場の成長を促進する主な要因としては、甲状腺障害の発生率の増加、特に新興国における疾患啓発プログラムの増加、甲状腺障害を治療するための効果的な薬剤併用療法の開発などが挙げられます。世界中の政府機関が、甲状腺障害のタイムリーな診断と治療に関する認識を高め、市場の成長を促進しています。さらに、製薬メーカーも啓発キャンペーンを支援したり、市場の成長を促進すると予想される認知度を高めるためのプロモーション戦略を実施したりする取り組みを行っています。

甲状腺障害市場は、ヨウ素欠乏症の患者数が増加していることが主な要因です。甲状腺関連疾患の研究開発と医薬品部門への投資の増加が市場を牽引する可能性があります。しかし、放射性ヨウ素（RAI）療法などの治療法が高額であることや、利用可能な治療薬に関連する副作用などの要因が、市場の成長をある程度抑制する可能性があります。

目次

第1章 世界の甲状腺障害市場のイントロダクション

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 世界の甲状腺障害の市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル

第5章 甲状腺障害の世界市場：タイプ別

• 概要
• 甲状腺機能低下症
• 甲状腺機能亢進症

第6章 甲状腺障害の世界市場：治療別

• 概要
• 薬物療法
• 放射性ヨード治療
• 手術療法

第7章 世界の甲状腺障害市場：投与経路別

• 概要
• 経口
• 静脈内投与
• その他

第8章 甲状腺障害の世界市場：エンドユーザー別

• 概要
• 病院
• 診療所
• その他

第9章 甲状腺障害の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第10章 世界の甲状腺障害市場の競合情勢

• 概要
• 各社の市場ランキング
• 主な開発戦略

第11章 企業プロファイル

• AbbVie Inc.
• Pfizer Inc.
• Merck & Co.
• Lannett Company, Inc.
• Allergan PLC
• Mylan N.V.
• GlaxoSmithKline PLC
• Novartis AG
• RLC LABS
• Abbott Laboratories

第12章 付録

• 関連調査

Thyroid Disorder Market Size And Forecast

Thyroid Disorder Market size was valued at USD 2.46 Billion in 2024 and is projected to reach USD 3.35 Billion by 2032, growing at a CAGR of 3.17 % during the forecast period 2026-2032.

The rising number of thyroid gland disorders, the introduction of new effective combination drug therapies, and the growing number of cases requiring effective combination drug therapies are some of the factors anticipated to foster market growth during the forecast period. The Global Thyroid Disorder Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors playing a substantial role in the market.

Global Thyroid Disorder Market Definition

Thyroid disorders are medical conditions affecting the proper functioning of the thyroid gland. The thyroid gland is an endocrine gland located in the middle of lower the neck and is responsible for the production of thyroid hormones which help to regulate various metabolic activities in the body. The thyroid controls the body's cells use energy from food, a process called metabolism. Among other things, metabolism affects the body's temperature, heartbeat, and how well the body burns calories. If the body doesn't have enough thyroid hormone, human body processes slow down.

When the thyroid gland does not produce enough thyroid hormones (hypothyroidism) or too much hormone (hyperthyroidism), the metabolism and functioning of the body are disrupted. The lack of iodine in the body is a major factor that leads to thyroid disorders. All thyroid diseases can be treated, resulting in normal thyroid function. However, this frequently requires being on medication to maintain a normal thyroid state. Most patients with thyroid disorders can be cured through surgery and radioactive iodine treatments.

Global Thyroid Disorder Market Overview

The major factors that drive the growth of the market include an increase in the incidence of thyroid gland disorder, a rise in the number of disease awareness programs, especially in developing countries, and the development of effective combination drug therapies to treat thyroid gland disorder. A government organization across the globe has increased the awareness about timely diagnosis and treatment of thyroid disorders hence promoting the growth of the market. In addition, pharmaceutical manufacturers are also undertaking initiatives to support awareness campaigns or implement promotional strategies to create awareness anticipated to propel the growth of the market.

The market for thyroid disorders is primarily driven by the increasing number of patients with iodine deficiency cause of very less good sources of iodine in the diet can drive the market growth. Research and the development of medicines for thyroid-related disorders and an increase in the investments made in the pharmaceutical sector can drive the market. However, factors such as the high cost of treatment procedures such as radioactive iodine (RAI) therapy and side effects related to the available therapeutics might restrain the market growth to an extent.

Global Thyroid Disorder Market: Segmentation Analysis

The Global Thyroid Disorder Market is Segmented on the basis of Type, Treatment, Route Of Administration, End User, and Geography.

Thyroid Disorder Market, By Type

• Hypothyroidism
• Hyperthyroidism

Based on Type, The market is bifurcated into Hypothyroidism and Hyperthyroidism. If the body makes too much thyroid hormone, the body can develop a condition called hyperthyroidism. If the body makes too little thyroid hormone, it's called hypothyroidism. Both conditions are serious and need to be treated with effective drug therapies. Hypothyroidism is expected to gain significant traction over the forecast period. A growing population base diagnosed with the condition and the rising prevalence of iodine deficiency population across the globe is some of the factors that boost the market growth.

Thyroid Disorder Market, By Treatment

• Medications
• Radioactive Iodine Therapy
• Surgery

Based on Treatment, The market is bifurcated into Medications, Radioactive Iodine Therapy and Surgery. Medication that boosts your levels of thyroid hormone is an easy way to treat hypothyroidism. It's not a cure, but it can keep patients' conditions under control for the long term. Also, radioactive iodine therapy is the most widely recommended permanent treatment of hyperthyroidism. This treatment takes advantage of the fact that thyroid cells are the only cells in the body that can absorb iodine.

Thyroid Disorder Market, By Route of Administration

• Oral
• Intravenous
• Others

Based on the Route Of Administration, The market is bifurcated into Oral, Intravenous, and Others. The oral route of the administration segment is the largest contributor toward market growth. Most of the medications available in the market are in the form of tablets or pills and can be easily administered by patients.

Thyroid Disorder Market, By End User

• Hospitals
• Clinics
• Others

Based on End Users, The market is bifurcated into Hospitals, Clinics, and Others.

Thyroid Disorder Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world

Based on Regional Analysis, The Global Thyroid Disorder Market is classified into North America, Europe, Asia Pacific, and Rest of the world. North America is dominating the thyroid gland disorder market. Multinational companies are frequently involved in raising awareness in American society through campaigns driving the growth of the market in the region. The Asia Pacific is expected to have significant growth during the forecast period owing to the growing population base affected with thyroid disorder is increasing demand for drugs that are further expected to boost the growth of the market.

Key Players

The "Global Thyroid Disorder Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are AbbVie Inc., Pfizer Inc., Merck & Co., Inc., Lannett Company, Inc., Allergan plc., Mylan N.V., GlaxoSmithKline plc., Novartis AG, RLC LABS, Inc., and Abbott Laboratories.

• The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL THYROID DISORDER MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL THYROID DISORDER MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model

5 GLOBAL THYROID DISORDER MARKET, BY TYPE

• 5.1 Overview
• 5.2 Hypothyroidism
• 5.3 Hyperthyroidism

6 GLOBAL THYROID DISORDER MARKET, BY TREATMENT

• 6.1 Overview
• 6.2 Medications
• 6.3 Radioactive Iodine Therapy
• 6.4 Surgery

7 GLOBAL THYROID DISORDER MARKET, BY ROUTE OF ADMINISTRATION

• 7.1 Overview
• 7.2 Oral
• 7.3 Intravenous
• 7.4 Others

8 GLOBAL THYROID DISORDER MARKET, BY END USER

• 8.1 Overview
• 8.2 Hospitals
• 8.3 Clinics
• 8.4 Others

9 GLOBAL THYROID DISORDER MARKET, BY GEOGRAPHY

• 9.1 Overview
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 U.K.
  • 9.3.3 France
  • 9.3.4 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Rest of Asia Pacific
• 9.5 Rest of the World
  • 9.5.1 Latin America
  • 9.5.2 Middle East and Africa

10 GLOBAL THYROID DISORDER MARKET COMPETITIVE LANDSCAPE

• 10.1 Overview
• 10.2 Company Market Ranking
• 10.3 Key Development Strategies

11 COMPANY PROFILES

• 11.1 AbbVie Inc.
  • 11.1.1 Overview
  • 11.1.2 Financial Performance
  • 11.1.3 Product Outlook
  • 11.1.4 Key Developments
• 11.2 Pfizer Inc.
  • 11.2.1 Overview
  • 11.2.2 Financial Performance
  • 11.2.3 Product Outlook
  • 11.2.4 Key Developments
• 11.3 Merck & Co.
  • 11.3.1 Overview
  • 11.3.2 Financial Performance
  • 11.3.3 Product Outlook
  • 11.3.4 Key Developments
• 11.4 Lannett Company, Inc.
  • 11.4.1 Overview
  • 11.4.2 Financial Performance
  • 11.4.3 Product Outlook
  • 11.4.4 Key Developments
• 11.5 Allergan PLC
  • 11.5.1 Overview
  • 11.5.2 Financial Performance
  • 11.5.3 Product Outlook
  • 11.5.4 Key Developments
• 11.6 Mylan N.V.
  • 11.6.1 Overview
  • 11.6.2 Financial Performance
  • 11.6.3 Product Outlook
  • 11.6.4 Key Developments
• 11.7 GlaxoSmithKline PLC
  • 11.7.1 Overview
  • 11.7.2 Financial Performance
  • 11.7.3 Product Outlook
  • 11.7.4 Key Developments
• 11.8 Novartis AG
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 RLC LABS
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Abbott Laboratories
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

12 APPENDIX

• 12.1 Related Research